New IV drug aims to give kidney patients better sleep
NCT ID NCT07380113
First seen Feb 02, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tests a new intravenous drug, Anrikefon, against a standard oral medication, nalfurafine, to see which improves sleep better in people with chronic kidney disease who also suffer from severe itching. Fifty adults on dialysis will receive one of the two treatments for four weeks. The main goal is to measure changes in sleep quality and overall well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.